| Literature DB >> 30234125 |
Andrea Giannini1, Silvia Pisaneschi1, Elisa Malacarne1, Vito Cela1, Franca Melfi2, Alessandra Perutelli1, Tommaso Simoncini1.
Abstract
Introduction: Surgical treatment of ureteral endometriosis is necessary to relieve urinary symptoms of obstruction and to preserve renal function. Which surgical approach to ureteral endometriosis should be considered the most appropriate is debated, due to the lack of scientific evidence. The aim of the present study is to assess the feasibility and to describe the perioperative outcomes of minimally invasive treatment of deep ureteral endometriosis using robotic assistance, highlighting the technical benefits and the limits of this approach. Method: A case-series including 31 consecutive patients affected by high-stage endometriosis including ureteral endometriosis using robotic assistance in our Department between November 2011 and September 2017.Entities:
Keywords: da Vinci Si; da Vinci Xi; gynecologic surgery; minimally invasive surgery; robotic; ureteral endometriosis
Year: 2018 PMID: 30234125 PMCID: PMC6131650 DOI: 10.3389/fsurg.2018.00051
Source DB: PubMed Journal: Front Surg ISSN: 2296-875X
Figure 1Different steps of surgical excision of endometriotic nodule involving the ureter. (A) Opening of the broad ligament and identification of the right ureter involved by an extrinsic lesion. (B) In case of extrinsic ureteral endometriosis, ureterolysis is accomplished using bipolar forceps and monopolar scissors until anatomical structures seem completely free from disease. (C) During the procedure, care is taken to minimize the risk of ureteral resection and injuries to surrounding structures, with a particular attention to preserving the nerves. (D) When skeletonization is concluded an accurate check of the whole pelvic ureter is performed to identify intraoperative lesions.
Patients characteristics.
| N. of case | 31 |
| Age (years ± SD) | 39.1 ± 4.56 |
| BMI (kg/m2 ± SD) | 22.97 (21.75%) |
| History of endometriosis surgery | 12 (38.7%) |
| Nulliparus | 20 (64.5%) |
| Primiparus or multiparus | 11 (35.4%) |
| Dysmenorrhea | 21 (67.7%) |
| Dyspareunia | 20 (64.5%) |
| Urinary tract signs | 13 (41.9%) |
| Digestive signs | 8 (25.8%) |
| I | 2 (6.4%) |
| II | 25 (80.6%) |
| III | 4 (12.9%) |
| IV | 0 |
| Perioperative hormonal treatment | 20 (64.5%) |
| Preoperative stenting | 9 (29%) |
ASA, American Society of Anesthesiologists.
Perioperative results.
| Operating time (min) | 184.8 ± 81 |
| Estimated blood loss | 207 ± 142 |
| Hospital stay (days) | 4.02 ± 3 |
| Full robotic technique | 31 (100%) |
| Three arms | 28 (90.3%) |
| Four arms | 3 (9.7%) |
| Side Docking | 29 (93.5%) |
| Right side | 22 (75.8%) |
| Left side | 7 (24.2%) |
| Central docking | 2 (6.5%) |
| Rectovaginal nodules | 6 (19.3%) |
| Uterosacral ligaments | 24 (77.4%) |
| Endometriomas | 7 (22.6%) |
| Left | 21 (67.7%) |
| Right | 10 (32.3%) |
| Ureteral fistula | 2 (6.4%) |
| Hydronephrosis | 1 (3.2%) |
| Vaginal hematoma | 1 (3.2%) |
| Ureterovescical reimplantation | 1 (3.2%) |
| Histopathology confirmation | 31 (100%) |